The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients

AIDS

Volumn 28, Issue 3, 2014, Pages 365-376

  Linas, Benjamin P ^a,b   Barter, Devra M ^a   Leff, Jared A ^c   DiLorenzo, Madeline ^d   Schackman, Bruce R ^c   Horsburgh, Charles R ^a,b   Assoumou, Sabrina A ^a   Salomon, Joshua A ^e   Weinstein, Milton C ^e   Kim, Arthur Y ^d   Freedberg, Kenneth A ^b,d,e  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; HIV hepatitis C virus coinfection; Interferon free; Telaprevir

Indexed keywords

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84894085529     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000093     Document Type: Article

References (100)

1. Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012; 32:1194-1199.
2. Food and Drug Administration. Approval of Incivek (TVRaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm. [Accessed 10 July 2013].
3. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with TVRaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86- 96.
4. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
5. Gilead Sciences. Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C. http://investors.gilead.com/ phoenix.zhtml?c=69964&p=irol-newsArticle&id=1804362 [Accessed 10 July 2013].
6. Gane E, Hyland R, Ding X, Pang P, McHutchison J, Symonds W, et al. 100% suppression of viral load through 4 weeks' posttreatment for sofosbuvir R ledipasvir (GS-5885) R ribavirin for 12 weeks in treatment-naïve and -experienced hepatitis C virus GT 1 patients. In: 20th Conference on Retroviruses and Opportunistic Infection; Atlanta, GA; 3-6 March 2013.
7. Lawitz E, Cohen D, Poordad F, Kowdley K, Everson G, Freilich B, et al. 12 weeks of ABT-450/ritonavir, nonnucleoside inhibitor and ribavirin achieved SVR24 in >90% of treatmentnai ?ve hepatitis C virus GT1 patients and 47% of prior nonresponders. In: 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA; 3-6 March 2013.
8. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez- Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEngl J Med 2013; 368:1867-1877.
9. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
10. Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int 2012; 32 (Suppl 1):129-134.
11. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859-1861.
12. Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med 2013; 21:27-35.
13. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomicbased treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106:38-45.
14. Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011; 6:e25753.
15. Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 2011; 18:e325-e331.
16. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
17. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012; 55:279-290.
18. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156:279-290.
19. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, et al. The impact of HIV/HCV co-infection on healthcare utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011; 18:506-512.
20. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-638.
21. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55:1332-1338.
22. Pineda JA, Aguilar-Guisado M, Rivero A, Giron-Gonzalez JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-1282.
23. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liverrelated morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-288288 e281.
24. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84-92.
25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
26. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson IM, et al. Sustained virologic response with daclatasvir plus sofosbuvir W ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed TVRaprevir (TVR) or boceprevir (BOC) In: European Association for the Study of the Liver; Netherlands, Amsterdam; 24-28 April 2013.
27. United States Department of Health and Human Services Center for Medicare Services. Physician Fee Schedule. http://www.cms.gov/Medicare/Medicare-Fee-for- Service-Pay ment/PhysicianFeeSched/index.html?redirect=/PhysicianFee Sched. [Accessed 15 January 2013].
28. United States Department of Health and Human Services Center for Medicare Services. Clinical Diagnostic Laboratory Fee Schedule. http://www.cms.gov/ ClinicalLabFeesched/02-clinlab.asp. [Accessed 1 February 2013].
29. University Health Systems Consortium. CDP Online Report. http://www.uhc.edu. [Accessed 30 January 2013].
30. Micromedex 2.0. Drug Topics Red Book Online. http://www. micromedexsolutions.com/micromedex2/librarian/. [Accessed 25 June 2013].
31. United States Department of Labor Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers. From: http://www.bls.gov/cpi/. [Accessed 15 January 2013].
32. Bamezai A, Melnick G, Nawathe A. The cost of an emergency department visit and its relationship to emergency department volume. Ann Emerg Med 2005; 45:483-490.
33. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339:1897-1904.
34. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, Josephs JS, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24:2705-2715.
35. Levinson D. Medicaid drug price comparisons: average manufacturer price to published prices. Department of Health and Human Services. http://www.oig.hhs.gov/oei/reports/oei-05- 05-00240.pdf. 2005. [Accessed 3 August 2013.]
36. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-997.
37. Paltiel AD, Scharfstein JA, Seage GR 3rd, Losina E, Goldie SJ, Weinstein MC, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998; 18:S93-S105.
38. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38.
39. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha- 2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432.
40. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002; 6:1-122.
41. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37: 1367-1375.
42. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19:357-365.
43. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361- 2369.
44. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003; 33:356-364.
45. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1039-1046.
46. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat 2006; 13:799-810.
47. Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIVcoinfected patients. J Antimicrob Chemother 2007; 60:1347- 1354.
48. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006; 11:131-142.
49. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
50. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
51. Aparicio E, Parera M, Franco S, Perez-Alvarez N, Tural C, Clotet B, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5:e13771.
52. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25:1415- 1420.
53. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-795.
54. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-450.
55. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV- 1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25:2259-2268.
56. Arendt M, Munk-Jorgensen P, Sher L, Jensen SO. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend 2011; 114:134-139.
57. Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619-627.
58. Akkarathamrongsin S, Sugiyama M, Matsuura K, Kurbanov F, Poovorawan Y, Tanaka Y, et al. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatol Res 2010; 40:956-962.
59. Kani S, Tanaka Y, Matsuura K, Watanabe T, Yatsuhashi H, Orito E, et al. Development of new IL28B genotyping method using Invader Plus assay. Microbiol Immunol 2012; 56:318-323.
60. Lin M, Rouster SD, Charlton A, Sherman KE. High-resolution melting analysis: a rapid and accurate alternative method for the detection of IL28B single-nucleotide polymorphisms. In: Conference on Retroviruses and Opportunistic Infections. Seattle; 5-8 March 2012.
61. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
62. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
63. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. 1995 ed. Springfield, VA: National Technical Information Service.
64. Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991; 324: 580-584.
65. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
66. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995; 333:615-620.
67. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177-188.
68. Pedrol E, Gonzalez-Clemente JM, Gatell JM, Mallolas J, Miro JM, Graus F, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS 1990; 4:511-517.
69. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992; 326:793-798.
70. Wheat J, Hafner R, Wulfsohn M, Spencer P, Squires K, Powderly W, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:610-616.
71. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
72. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided TVRaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
73. Dieterich D, Soriano V, Sherman KE, Girard P-M, Rockstroth JK, Henshaw J, et al. TVRaprevir in combination with peginterferon Alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. In: Conference for Retroviruses and Opportunistic Infections; Seattle, Washington; 5-8 March 2012.
74. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609- 2617.
75. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
76. Grinsztejn B, Nguyen B, Katlama C, Gatell J, Lazzarin A, Vittecog D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
77. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
78. Lalezari JP, Goodrich J, deJesus E, Lampiris H, Gulick R, Saag M, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: Conference on Retroviruses and Opportunistic Infections; Los Angeles, CA; 25-28 February 2007.
79. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404- 412.
80. Flieishman J. HIV loss to follow up data from the HIV Research Network. In: Linas B, editor; 2013.
81. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor- based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012; 12:335-343.
82. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
83. Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making 2008; 28:233-242.
84. Food and Drug Administration. TVRaprevir package insert. http://www.fda.gov. [Accessed 7 August 2013].
85. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17:531-546.
86. Daltro-Oliveira R, Morais-de-Jesus M, Pettersen KM, Parana R, Quarantini LC. Impact of sustained virologic response on quality of life in chronic HCV carriers. Ann Hepatol 2013; 12:399-407.
87. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30:1299-1301.
88. Vera-Llonch M, Martin M, Aggarwal J, Donepudi M, Bayliss M, Goss T, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving TVRaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013; 38:124-133.
89. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of healthcare programmes. 3rd ed. Oxford: Oxford University Press; 2005.
90. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
91. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14:259-265.
92. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflatioñ Arch Intern Med 2003; 163:1637-1641.
93. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50 000 per quality-adjusted life-year decision rule?. Med Care 2008; 46:349-356.
94. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIVcoinfected persons. N Engl J Med 2004; 351:451-459.
95. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
96. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14:501-511.
97. Poordad FF. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010; 31:1251-1267.
98. Gellad Z. The cost-effectiveness of a TVRaprevir-inclusive regimen as initial therapy for genotype 1 hepaticis C infection in individuals with the CC IL28B polymorphism. In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 4-11 November 2011; San Francisco.
99. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54:1259-1271.
100. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013:1-11.